Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)

被引：0
|
作者：
Hainsworth, JD
Sosman, JA
Spigel, DR
Schwert, RC
Carrell, DL
Hubbard, F
Greco, FA
机构：
[1] Sarah Cannon Canc Ctr, Tennessee Oncol, Nashville, TN USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Grand Rapids CCOP, Grand Rapids, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4502
引用
收藏
页码：382S / 382S
页数：1
相关论文
共 50 条
  • [1] Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial.
    Spigel, DR
    Hainsworth, JD
    Sosman, JA
    Raefsky, EL
    Meluch, AA
    Edwards, D
    Horowitz, P
    Thomas, K
    Yost, K
    Stagg, MP
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 387S - 387S
  • [2] Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC).
    Bukowski, R. M.
    Kabbinavar, F.
    Figlin, R. A.
    Flaherty, K.
    Srinivas, S.
    Vaishampayan, U.
    Drabkin, H.
    Dutcher, J.
    Scappaticci, F.
    McDermott, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 222S - 222S
  • [3] A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma
    Mudigonda, Tejaswi V.
    Wyman, Kenneth
    Spigel, David R.
    Dahlman, Kimberly B.
    Greco, F. Anthony
    Puzanov, Igor
    Kelley, Mark C.
    Hainsworth, John D.
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (01) : 101 - 103
  • [4] Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC).
    Green, D
    Meza-Junco, J
    Arce, C
    Chavez-Macgregor, M
    de la Peña, R
    Sotomayor, M
    Gabilondo, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 443S - 443S
  • [5] A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)
    Chung, E. K.
    Posadas, E. M.
    Kasza, K.
    Karrison, T.
    Manchen, E.
    Michalak, L.
    Hahn, O. M.
    Stadler, W. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma
    Jonasch, E.
    Tsavachdidou, D.
    Wood, C. G.
    Matin, S. F.
    Corn, P. G.
    Tamboli, P.
    Wang, X.
    Tannir, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
    Dickler, Maura N.
    Rugo, Hope S.
    Eberle, CareyA.
    Brog, Edi
    Caravelli, James F.
    Panageas, Katherine S.
    Boyd, Jeff
    Yeh, Benjamim
    Lake, Diana E.
    Dang, Chau T.
    Gilewski, Teresa A.
    Bromberg, Jacqueline F.
    Seidman, Andrew D.
    D'Andrea, Gabriella M.
    Moasser, Mark M.
    Melisko, Michele
    Park, John W.
    Dancey, Janet
    Norton, Larry
    Hudis, Clifford A.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7878 - 7883
  • [8] A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma
    Chung, Elizabeth K.
    Posadas, Edwin M.
    Kasza, Kristen
    Karrison, Theodore
    Manchen, Elizabeth
    Hahn, Olwen M.
    Stadler, Walter M.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 150 - 154
  • [9] A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma
    Bedano, P. M.
    Perkins, S.
    Burns, M.
    Kessler, K.
    Nelson, R.
    Schneider, B. P.
    Risley, L.
    Dropcho, S.
    Loehrer, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial.
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Patton, JF
    Thompson, DS
    Sutton, V
    Hart, LL
    Yost, K
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 388S - 388S
12345